Annals of Behavioral Medicine

, 19:230 | Cite as

Behavioral issues in the efficacy versus effectiveness of pharmacologic agents in the prevention of cardiovascular disease

  • Thomas A. Pearson
  • William Feinberg
Mini-Series: Prevention of Cardiovascular Disease


A number of pharmacologic interventions are now recommended for the prevention of cardiovascular disease, based on the results of randomized controlled trials. These include antihypertensive drugs, lipid-lowering agents, antiplatelet and anticoagulant drugs, estrogen replacement therapy, beta-blockers, and angiotensin converting enzyme (ACE) inhibitors. It is likely that additional pharmacologic interactions will soon be proven efficacious. Despite the strength of this evidence and the development of clinical guidelines incorporating their use, a surprisingly low proportion of patients are actively treated with these agents. There may be a variety of explanations for this, including barriers at the level of the patient, health care provider, and health care institution. Finally, a number of questions remain as to the optimal combination of interventions, both behavioral and pharmacologic, which will yield maximal reduction in risk. The description of factors which reduce the effectiveness of pharmacologic interventions below the efficacy demonstrated in randomized clinical trials should be a fertile area for epidemiologic and behavioral research. *** DIRECT SUPPORT *** A00FV011 00007


Aspirin Atrial Fibrillation Angiotensin Converting Enzyme Coronary Disease Beta Carotene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. (1).
    Smith SC, Blair SN, Criqui MH, et al: Preventing heart attack and death in patients with coronary disease.Circulation. 1995,92: 2–4.PubMedGoogle Scholar
  2. (2).
    Pearson TA, Marx HJ: Reduction of risk in the patient with cardiovascular disease. In Pearson TA Criqui MH, Luepker RV, Oberman A, Winston M (eds),Primer in Preventive Cardiology. Dallas, TX: American Heart Association, 1994, 235–237.Google Scholar
  3. (3).
    Vogel RA: Risk factor intervention and coronary artery disease: Clinical strategies.Coronary Artery Disease. 1995,6: 466–471.PubMedGoogle Scholar
  4. (4).
    Pearson TA, McBride PE, Houston-Miller N, Smith SC: Organization of preventive cardiology service.Journal of the American College of Cardiology. 1996,27: 1039–1047.PubMedCrossRefGoogle Scholar
  5. (5).
    Forrester JF, Merz NB, Bush TL, et al: Task Force 4. Efficacy of risk factor management.Journal of the American College of Cardiology. 1996,27: 991–1006.PubMedCrossRefGoogle Scholar
  6. (6).
    Collins R, Peto R, McMahon S, et al: Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: Overview of randomized drug trials in their epidemiological context.The Lancet. 1990,335: 827–839.CrossRefGoogle Scholar
  7. (7).
    McMahon S, Peto R, Cutler J, et al: Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: Prospective studies corrected for regression dilution bias.The Lancet. 1990,335: 765–774.CrossRefGoogle Scholar
  8. (8).
    SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension.Journal of the American Medical Association. 1991,265: 3255–3264.CrossRefGoogle Scholar
  9. (9).
    McMahon S, Rodgers A: Blood pressure, antihypertensive treatment, and stroke risk.Journal of Hypertension. 1994,12(Suppl. 10): S5-S14.Google Scholar
  10. (10).
    Hebert PR, Moser M, Mayer J, Hennekens CH: Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary artery disease.Archives of Internal Medicine. 1993,153: 578–581.PubMedCrossRefGoogle Scholar
  11. (11).
    The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V).Archives of Internal Medicine. 1993,153: 154–183.Google Scholar
  12. (12).
    Goldman L, Garber AM, Grover SA, Hlatky MA: Task Force 6. Cost effectiveness of assessment and management of risk factors.Journal of the American College of Cardiology. 1996,27(5): 1020–1030.PubMedCrossRefGoogle Scholar
  13. (13).
    Littenberg B, Garber AM, Sox Jr. HJ: Screening for hypertension.Annals of Internal Medicine. 1990,112: 192–202.PubMedGoogle Scholar
  14. (14).
    Littenberg B: A practice guideline revisited: Screening for hypertension.Annals of Internal Medicine. 1995,122: 937–939.PubMedGoogle Scholar
  15. (15).
    Levine DM, Green LW, Deeds SG, et al: Health education for hypertensive patients.Journal of the American Medical Association. 1979,241: 1700–1703.PubMedCrossRefGoogle Scholar
  16. (16).
    Morisky DE, Levine DM, Green LW, et al: Five-year blood pressure control and mortality following health education for hypertensive patients.American Journal of Public Health. 1983,73: 153–162.PubMedCrossRefGoogle Scholar
  17. (17).
    Haynes RB, Dantes R: Patient compliance and the conduct and interpretation of therapeutic trials.Controlled Clinical Trials. 1987,8: 12–19.PubMedCrossRefGoogle Scholar
  18. (18).
    Working Group on Health Education and High Blood Pressure Control:The Physicians Guide: Improving Adherence Among Hypertensive Patients. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, 1987.Google Scholar
  19. (19).
    Levine DM, Cohen DJ, Dustan HP, et al: Behavior changes and the prevention of high blood pressure. Workshop II. AHA Prevention Conference III. Behavior change and compliance: Keys to improving cardiovascular health.Circulation. 1993,88: 1387–1390.PubMedGoogle Scholar
  20. (20).
    Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).Journal of the American Medical Association. 1993,269: 3015–3033.Google Scholar
  21. (21).
    Rossouw JE: Secondary prevention of coronary heart disease. In Rifkin BM (ed),Lowering Cholesterol in High-Risk Individuals and Populations. New York: Marcel Dekker, 1995, 49–67.Google Scholar
  22. (22).
    Treasure CB, Klein JL, Weintraub WS, et al: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease.New England Journal of Medicine. 1995,332: 481–487.PubMedCrossRefGoogle Scholar
  23. (23).
    Anderson TJ, Meredith IT, Yeung AC, et al: The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion.New England Journal of Medicine. 1995,332: 488–493.PubMedCrossRefGoogle Scholar
  24. (24).
    Egashira K, Hirooka Y, Kai H, et al: Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia.Circulation. 1994,89: 2519–2524.PubMedGoogle Scholar
  25. (25).
    Gould KL, Martucci JP, Goldberg DI, et al: Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease.Circulation. 1994,89: 1530–1538.PubMedGoogle Scholar
  26. (26).
    Andrews TC, Raby K, Barry J, et al: The effect of LDL cholesterol reduction on myocardial ischemia in patients with coronary disease.Circulation. 1997,95: 324–327.PubMedGoogle Scholar
  27. (27).
    Brown GB, Zhao Y-Q, Sacco DE, et al: Lipid-lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease.Circulation. 1993,87: 1781–1789.PubMedGoogle Scholar
  28. (28).
    Post Coronary Artery Bypass Graft Trial Investigators: The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous vein coronary artery bypass grafts.New England Journal of Medicine. 1997,336: 153–162.CrossRefGoogle Scholar
  29. (29).
    Scandinavian Simvastatin Survival Group: Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S).The Lancet. 1994,344: 1383–1389.CrossRefGoogle Scholar
  30. (30).
    Sacks FM, Pfeffer MA, Moye LA, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.New England Journal of Medicine. 1996,335: 1001–1009.PubMedCrossRefGoogle Scholar
  31. (31).
    Shepherd J, Cobbe SM, Ford I, et al. for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.New England Journal of Medicine. 1995,333: 1301–1307.PubMedCrossRefGoogle Scholar
  32. (32).
    Goldman L, Garber AM, Grover SA, Hlatky MA: Task Force 6. Cost effectiveness of assessment and management of risk factors.Journal of the American College of Cardiology. 1996,27: 1020–1030.PubMedCrossRefGoogle Scholar
  33. (33).
    Giles WH, Anda RF, Jones DH, et al: Recent trends in the identification and treatment of high blood cholesterol by physicians. Progress and missed opportunities.Journal of the American Medical Association. 1993,269: 1133–1138.PubMedCrossRefGoogle Scholar
  34. (34).
    Cohen MV, Byrne M-J, Levine B, Gutowski T, Adelson R: Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease.Circulation. 1991,83: 1294–1304.PubMedGoogle Scholar
  35. (35).
    Marcelino JJ, Feingold KR: Inadequate treatment with HMG-CoA reductase inhibitors by health care providers.American Journal of Medicine. 1996,100: 605–610.PubMedCrossRefGoogle Scholar
  36. (36).
    Andrade S, Walker D, Gottlieb L, et al: Discontinuation of antihyperlipidemia drugs—Do rates reported in clinical trials reflect rates in primary care settings?New England Journal of Medicine. 1995,332: 1125–1131.PubMedCrossRefGoogle Scholar
  37. (37).
    Simons LA, Levis G, Simon J: Apparent discontinuation rates in patients prescribed lipid-lowering drugs.Medical Journal of Australia. 1996,164: 208–211.PubMedGoogle Scholar
  38. (38).
    Antiplatelet Trialists' Collaboration: Collaborative overview of randomized trials of antiplatelet therapy-I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.British Medical Journal. 1994,308: 81–106.Google Scholar
  39. (39).
    Cairns JA, Markham BA: Economics and efficacy in choosing oral anticoagulants or aspirin after myocardial infarction.New England Journal of Medicine. 1995,273: 965–967.Google Scholar
  40. (40).
    Patrono C: Aspirin as an antiplatelet drug.New England Journal of Medicine. 1994,330: 1287–1294.PubMedCrossRefGoogle Scholar
  41. (41).
    Matchar DB, McCrory DC, Barnett HJM, Feussner JR: Medical treatment for stroke prevention.Annals of Internal Medicine. 1994,121: 41–53.PubMedGoogle Scholar
  42. (42).
    ISIS-2 (Second International Study of Infarct Survival) Collaborative Study Group: Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187, cases of suspected acute myocardial infarction: ISIS-2.The Lancet. 1988,2: 349–360.Google Scholar
  43. (43).
    Hirsh J, Dalen JE, Fuster VF, et al: Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side effects.Chest. 1995,108(Suppl.): 247S-257S.PubMedCrossRefGoogle Scholar
  44. (44).
    Hart RG, Harrison MJG: Aspirin wars: The optimal dose of aspirin to prevent stroke.Stroke. 1996,27: 585–587.PubMedGoogle Scholar
  45. (45).
    Dyken ML, Barnett HJM, Easton JD, et al: Low-dose aspirin and stroke: “It ain't necessarily so.”Stroke. 1992,23: 1395–1399.PubMedGoogle Scholar
  46. (46).
    Patrono C, Roth GJ: Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen?Stroke. 1996,27: 756–760.PubMedGoogle Scholar
  47. (47).
    Cairns JA, Lewis HD, Meade TW, Sutton GC, Thèroux P: Antithrombotic agents in coronary artery disease.Chest. 1995,108(Suppl.): 380S-400S.PubMedCrossRefGoogle Scholar
  48. (48).
    Smith P, Arnesen H, Holme I: The effect of warfarin on mortality and reinfarction after myocardial infarction.New England Journal of Medicine. 1990,323: 147–152.PubMedGoogle Scholar
  49. (49).
    Anticoagulation in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group: Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction.The Lancet. 1994,343: 499–503.Google Scholar
  50. (50).
    Laupacis A, Albers GW, Dalen JE, et al: Antithrombotic therapy for atrial fibrillation.Chest. 1995,108(Suppl.): 352S-359S.PubMedCrossRefGoogle Scholar
  51. (51).
    Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials.Archives of Internal Medicine. 1994,154: 1449–1457.CrossRefGoogle Scholar
  52. (52).
    Albers GW: Atrial fibrillation and stroke. Three new studies, three remaining questions.Archives of Internal Medicine. 1994,154: 1443–1448.PubMedCrossRefGoogle Scholar
  53. (53).
    McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett ELC: Physician attitudes about anticoagulation for non-valvular atrial fibrillation in the elderly.Archives of Internal Medicine. 1995,155: 277–281.PubMedCrossRefGoogle Scholar
  54. (54).
    Agency for Health Care Policy and Research: Life-saving treatments to prevent stroke underused.Research Activities. 1995,187(September): 1–2.Google Scholar
  55. (55).
    Barrett-Connor E, Bush RL: Estrogen and coronary heart disease in women.Journal of the American Medical Association. 1991,265: 1861–1867.PubMedCrossRefGoogle Scholar
  56. (56).
    Stampfer MH, Colditz GA: Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence.Preventive Medicine. 1991,20: 47–63.PubMedCrossRefGoogle Scholar
  57. (57).
    Sullivan JM, Vander Zwaag R, Lemp GF, et al: Postmenopausal estrogen use and coronary atherosclerosis.Annals of Internal Medicine. 1988,108: 358–363.PubMedGoogle Scholar
  58. (58).
    Gruchow HW, Anderson AJ, Barboriak JJ, Sobocinski KA: Postmenopausal estrogen use of estrogen and occlusion of coronary arteries.American Heart Journal. 1988,115: 954–963.PubMedCrossRefGoogle Scholar
  59. (59).
    McFarland KF, Boniface ME, Hornung CA, Barnhardt W, Humphries JO: Risk factors and non-contraceptive estrogen use in women with and without coronary disease.American Heart Journal. 1989,117: 1209–1214.PubMedCrossRefGoogle Scholar
  60. (60).
    Sullivan JM, Vander Zwaag R, Hughes JP, et al: Estrogen replacement and coronary artery disease: Effects on survival in post menopausal women.Archives of Internal Medicine. 1990,150: 2557–2562.PubMedCrossRefGoogle Scholar
  61. (61).
    O'Keefe JH, Kun SC, Hall RR, et al: Estrogen replacement therapy after coronary angioplasty.Journal of the American College of Cardiology. 1997,29: 1–5.PubMedCrossRefGoogle Scholar
  62. (62).
    The Writing Group for the PEPI Trial: Effect of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.Journal of the American Medical Association. 1996,273: 199–208.Google Scholar
  63. (63).
    Hennekens CH, Albert CM, Godfried SL, Gaziano JM, Buring JE: Adjunctive drug therapy of acute myocardial infarction. Evidence from clinical trials.New England Journal of Medicine. 1996,335: 1660–1667.PubMedCrossRefGoogle Scholar
  64. (64).
    ASPIRE Steering Group: A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action in Secondary Prevention through Intervention to Reduce Events. Principal Results).Heart. 1996,75: 334–342.CrossRefGoogle Scholar
  65. (65).
    Philbin EF, Andreou C, Rocco Jr. TA, Lynch LJ, Baker SL: Patterns of angiotensin converting enzyme inhibitor use in congestive heart failure in two community hospitals.American Journal of Cardiology. 1996,77: 832–838.PubMedCrossRefGoogle Scholar
  66. (66).
    Furberg CD, Psaty BM, Meyer JV: Nifedipine: Dose-related increase in mortality in patients with coronary heart disease.Circulation. 1995,92: 1326–1331.PubMedGoogle Scholar
  67. (67).
    The Alpha-Tocophenol, Beta Carotene Cancer Prevention Study Group: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers.New England Journal of Medicine. 1994,330: 1029–1035.CrossRefGoogle Scholar
  68. (68).
    Stephen NG, Parson A, Schofield PM, et al: Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS).The Lancet. 1996,347: 781–786.CrossRefGoogle Scholar
  69. (69).
    Berg JS, Dischler J, Wagner DJ, Raia JJ, Palmer-Shelvin N: Medication compliance: A health care problem.Annals of Pharmacotherapy. 1993,27(Suppl.): S2-S22.Google Scholar
  70. (70).
    Horwitz RI, Viscoli CM, Berkman L, et al: Treatment adherence and risk of death after a myocardial infarction.The Lancet. 1990,336: 542–545.CrossRefGoogle Scholar
  71. (71).
    Gallagher EJ, Viscoli CM, Horwitz RI: The relationship of treatment adherence to the risk of death after myocardial infarction in women.Journal of the American Medical Association. 1993,270: 742–744.PubMedCrossRefGoogle Scholar
  72. (72).
    Levine DM: Behavioral and psychosocial factors, processes, and strategies. In Pearson TA, Criqui MH, Luepker RV, et al (eds),Primer in Preventive Cardiology. Dallas, TX: American Heart Association, 1994, 217–226.Google Scholar
  73. (73).
    Eraker SA, Knight JP, Becker MH: Understanding and improving patient compliance.Annals of Internal Medicine. 1984,100: 258–268.PubMedGoogle Scholar
  74. (74).
    Luepker RV: Patient adherence: A “risk factor” for cardiovascular disease.Heart Disease and Stroke. 1993, 419–421.Google Scholar
  75. (75).
    The Pooling Project Research Group: Relationships of blood pressure, serum cholesterol, smoking habit, relative weight, and ECG abnormalities to incidence of major coronary events: Final report of the pooling project.Journal of Chronic Diseases. 1978,31: 201–306.CrossRefGoogle Scholar
  76. (76).
    Avins AL, Browner WS: Lowering risk without lowering cholesterol: Implications for National Cholesterol Policy.Annals of Internal Medicine. 1996,125: 502–506.PubMedGoogle Scholar

Copyright information

© The Society of Behavioral Medicine 1997

Authors and Affiliations

  • Thomas A. Pearson
    • 1
  • William Feinberg
    • 2
  1. 1.Department of Community and Preventive MedicineUniversity of Rochester School of MedicineRochester
  2. 2.Arizona Health Sciences CenterUSA

Personalised recommendations